.webp&w=828&q=75)
AuKing Mining (ASX: AKN) Draws Renewed Attention: Drilling Catalysts Meet a Critical Technical Crossroads
AuKing Mining raised A$5 million to expand Tundulu drilling to 15,000 metres after logging carbonatite in 26 of 27 holes. However, assays remain pending, dilution is increasing, and bearish RSI divergence warns that momentum may be fading.
.webp&w=828&q=75)
VHM (ASX: VHM) at Support: Will Fundamental Catalysts Spark a Technical Upswing?
VHM Limited (ASX: VHM) advances its Tier‑1 Goschen critical minerals project toward FID, backed by full permitting, government financing interest, expanded resources and strategic offtake optionality. Strong regulatory momentum and project scale position VHM for a major rerating
St George Mining (ASX: SGQ): Broken Support Confirms Bearish Sentiment
St George Mining is a pre-revenue critical-minerals explorer advancing its 100%-owned Araxá rare earths-niobium project in Brazil. Resource growth, funding, studies and potential partnerships offer upside, while dilution, execution and commodity-price risks remain material
.webp&w=828&q=75)
Wildcat Resources (ASX: WC8): Lithium Scale, Strategic Momentum and High-Conviction Growth
Wildcat Resources (ASX: WC8) advances its Pilbara lithium portfolio with expanding high-grade discoveries, a progressing DFS at Tabba Tabba, and strong cash reserves, positioning the company for transformational growth amid rising global lithium demand.
Invictus Energy (ASX: IVZ) – A Frontier Play with Optionality
We view Invictus Energy as a rare example of an explorer with a clear pathway to development in one of Africa’s last underexplored rift systems. The Mukuyu gas-condensate discovery in Zimbabwe’s Cabora Bassa Basin anchors the portfolio, while high-impact follow-up at Musuma-1 and a strategic financing partnership with Al Mansour Holdings (AMH) materially de-risk the next stage of value creation.
EchoIQ (ASX: EIQ): Tests Rising-Channel Support as US Expansion Builds Momentum
EchoIQ is expanding its US presence through new funding, partnerships, clinical research, and hospital deployments. Its AI-based cardiac software continues to gain commercial traction, while the chart shows a pullback to key support within a longer-term rising trend.